Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology.

With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders.

For more information, please visit: www.daiichisankyo.com.

Daiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is a member of the Daiichi Sankyo Group. To learn more about Daiichi Sankyo, Inc., please visit www.dsi.com.

211 Mt. Airy Road
Basking Ridge, NJ 07920

Tel: (908) 992-6400

Visit website

NEWS

Business

Movers & Shakers: Odyssey, Daiichi Sankyo, Atsena and More

While Biogen and Seagen made the biggest C-suite splashes this week, other companies across the biopharma industry also bolstered their leadership teams with new talent.

November 10, 2022

6 min read

Alex Keown

Drug Development

Daiichi Sankyo’s Ezharmia Becomes First EZH1/2 Inhibitor for Blood Cancer

Daiichi Sankyo won approval in Japan for Ezharmia, making it the first dual inhibitor of EZH1 and EZH2 to receive regulatory approval for ATL.

September 26, 2022

2 min read

Alex Keown

Biotech Bay

Remote Work Opportunities Abound at Pfizer, GRAIL, Regeneron and More

In a recent BioSpace poll, more than half of employers indicated they planned to continue recruiting employees remotely. We highlight just some of those jobs here.

September 21, 2022

5 min read

Lisa Munger

Mohammed Haneefa Nizamudeen_Getty Images

Drug Development

In Group of Firsts, ESMO Highlights Therapeutic Advances in Lung Cancer

NSCLC At ESMO: Pollution does indeed cause lung cancer; Tecentriq shows promise in poor prognosis patients, Amgen makes progress in KRAS G12-mutated disease and an update on a Daiichi Sankyo ADC.

September 14, 2022

6 min read

Gail Dutton

Pictured: Gilead sign in front of tree_JOSH EDELSO

Drug Development

Gilead, Merck, Daiichi Sankyo and more Preview ESMO Presentations

Gilead, Merck, Daiichi Sankyo, HUTCHMED and BMS previewed data to be presented at the European Society for Medical Oncology Congress 2022, taking place Sept. 9-13.

September 6, 2022

5 min read

Alex Keown

Drug Development

Gilead’s Trodelvy Gives Enhertu a Run for its Money in Metastatic Breast Cancer

Weeks after AstraZeneca and Daiichi Sankyo were able to move the bar in the treatment of metastatic breast cancer with Enhertu, Gilead is answering that challenge with Trodelvy.

August 16, 2022

3 min read

Alex Keown

Policy

Seagen Loses Patent Battle against Daiichi Sankyo as Merck Waits in the Wings

As the biotech world awaits the announcement of Merck’s anticipated buyout of Seagen, an arbitrator came down on the side of Daiichi Sankyo in a patent battle against the Seattle-based biotech.

August 15, 2022

3 min read

Mark Terry

FDA

FDA Review: Bayer, Daiichi Sankyo, AstraZeneca and More

Daiichi Sankyo and AstraZeneca report another first-in-class approval for Enhertu, Bayer snags an sNDA in metastatic hormone-sensitive prostate cancer and Merck faces contamination challenges with Januvia.

August 12, 2022

3 min read

Mark Terry

Drug Development

AstraZeneca and Daiichi Sankyo’s Enhertu Racks up Another Clinical Win in Breast Cancer (Updated)

AstraZeneca and Daiichi Sankyo’s Enhertu has been approved by the FDA as the first HER2-directed medicine for the treatment of patients with HER2-mutant metastatic NSCLC.

August 12, 2022

4 min read

Alex Keown

JOBS